SwedenBIO awards an annual prize to a life science company that has distinguished itself during the year and contributed to societal benefits that emphasize the importance of a successful life science industry in Sweden.
This year’s nominations for the SwedenBIO Award show the fantastic diversity that exists in Swedish life science. Swedish life science companies are gaining ground, not only through cutting-edge research and innovation, but through smart, cutting-edge business models and shared responsibility for addressing our health challenges.
The SwedenBIO Award is the industry’s own prize and is awarded in collaboration with HealthCap. The prize has been awarded every year since 2007 to recognize and reward successful and exemplary companies. This year’s five finalists have now been selected.
Here are the five finalists in alphabetical order:
ANTAROS MEDICAL is a fast-growing company that uses cutting-edge imaging technology to help drug development companies understand how drugs work in the body. They create cutting-edge knowledge and solutions, which is reflected in an impressive number of research publications and collaborations with pharmaceutical companies worldwide. They also attract many clinical studies to Sweden.
BICO has created high visibility in the life science industry. Through their focus on bio convergence, they develop innovative solutions that bring together biology and technologies such as robotics, data science, AI and 3D bioprinting. With their business model, they are a model that shows that Swedish life science companies can and should have high growth ambitions.
Through its enzymes, GENOVIS offers tools that facilitate and save time for research and drug development companies. Developing new innovative enzyme products facilitates the development and quality control of biopharmaceuticals and also for therapeutic applications in gene therapy.
VALNEVA put Sweden on the international vaccine map this year, with an agreement with the EU for up to 60 million doses of its Covid-19 vaccine and the establishment of a large-scale fill & finish factory that expanded the vaccine company’s production capacity in Sweden. By daring to invest, they turned the headwind of declining demand for travel vaccines into a tailwind.
XBRANE is scaling up and well on its way to bringing a portfolio of biosimilars to market, with six new patents granted and a marketing authorization application submitted to the European Medicines Agency (EMA). With biosimilars, the production costs of biological medicines can be greatly reduced, making them available to more people.
The winner will be announced on December 8 at 17.00 at the Grand Hôtel in Stockholm.
Media are invited to attend the award ceremony that concludes the SwedenBIO Summit. If you are interested in attending the SwedenBIO Summit, please contact Helena Strigård.
The jury consists of SwedenBIO’s board of directors: Lotta Ljungqvist, Testa Center-Cytiva, Christine Wesström, Sobi, Anders Persson, AstraZeneca, Kertin Falck, Pfizer, Niels Abel Bonde, Novo Nordisk Sweden, Per Samuelsson, HealthCap, Sana Alajmovic, Sigrid Therapeutics, Torkel Gren, Recipharm and Lars Bäckman, Biotage.
Lotta Ljungqvist, Chairman of the Board
SwedenBIO, email@example.com, 070-622 62 84